Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Codopar is a branded generic combination analgesic containing codeine phosphate and paracetamol (acetaminophen). It is manufactured by Quest Pharmaceuticals in Nepal for the management of mild to moderate pain. Paracetamol provides analgesic and antipyretic effects, likely through the inhibition of prostaglandin synthesis in the central nervous system. Codeine is an opioid analgesic that acts as a mu-opioid receptor agonist after being metabolized to morphine, altering the perception of pain. This combination is typically used when single-ingredient analgesics are insufficient for pain control.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on codeine + paracetamol.